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Abstract
Introduction In view of the limited success of available
treatment modalities for metastatic breast cancer, alternative
and complementary strategies need to be developed.
Adenoviral vector mediated strategies for breast cancer gene
therapy and virotherapy are a promising novel therapeutic
platform for the treatment of breast cancer. However, the
promiscuous tropism of adenoviruses (Ads) is a major concern.
Employing tissue specific promoters (TSPs) to restrict
transgene expression or viral replication is an effective way to
increase specificity towards tumor tissues and to reduce
adverse effects in non-target tissues such as the liver. In this
regard, candidate breast cancer TSPs include promoters of the
genes for the epithelial glycoprotein 2 (EGP-2),
cyclooxygenase-2 (Cox-2), α-chemokine SDF-1 receptor
(stromal-cell-derived factor, CXCR4), secretory leukoprotease
inhibitor (SLPI) and survivin.
Methods We employed E1-deleted Ads that express the
reporter gene luciferase under the control of the promoters of
interest. We evaluated this class of vectors in various
established breast cancer cell lines, primary breast cancer cells
and finally in the most stringent preclinical available substrate
system, constituted by precision cut tissue slices of human
breast cancer and liver.
Results Overall, the CXCR4 promoter exhibited the highest
luciferase activity in breast cancer cell lines, primary breast
cancer cells and breast cancer tissue slices. Importantly, the
CXCR4 promoter displayed a very low activity in human primary
fibroblasts and human liver tissue slices. Interestingly, gene
expression profiles correlated with the promoter activities both
in breast cancer cell lines and primary breast cancer cells.
Conclusion These data suggest that the CXCR4 promoter has
an ideal 'breast cancer-on/liver-off' profile, and could, therefore,
be a powerful tool in Ad vector based gene therapy or
virotherapy of the carcinoma of the breast.
Introduction
Breast cancer is the most common cancer in the world. It
affects 1 in 9 women in the United States where 46,000
women die from breast cancer each year despite early
detection methods and advanced conventional treatments [1].
Clearly, novel therapies for breast cancer are required. Gene
therapy and virotherapy constitute a novel therapeutic
approach for the treatment of advanced, recurrent and meta-
static breast cancer. In gene therapy approaches, a therapeu-
tic gene for mutation compensation, immunopotentiation, or
Ad = adenovirus; BSA = bovine serum albumin; CAR Coxsackie-Adenovirus-Receptor; CMV = cytomegalovirus; Cox = cyclooxygenase; CXCR4 = 
α-chemokine SDF-1 receptor; DAPI = 4',6-diamidino-2-phenylindole dihydrochloride; EGP = epithelial glycoprotein; FCS = fetal calf serum; GAPDH 
= glyceraldehyde-3-phosphate dehydrogenase; MOI = multiplicity of infection; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; 
SLPI = secretory leukoprotease inhibitor; TSP = tissue specific promoter; UAB = University of Alabama at Birmingham; UW = University of Wiscon-
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prodrug activation is transferred [2]. In virotherapy, tumor cell
killing is achieved by oncolysis – virus replication induced cell
killing [3]. Both of these therapeutic interventions allow for
specific antitumor effects via molecular targeting strategies
that exploit tumor markers.
At present, the most promising gene delivery vehicle is the
recombinant adenoviral vector [4]. Whereas adenoviral vec-
tors are understood to exhibit superior levels of in vivo gene
transfer compared to available alternative vector systems, their
present level of efficiency in clinical trials may nonetheless be
suboptimal for cancer gene therapy and virotherapy applica-
tions [2]. Poor tumor cell transduction and non-specific cell
infection are key factors limiting realization of the potential of
breast cancer gene therapy [3,5]. Various approaches have
been developed to enhance the infectivity of current vector
systems to address poor cell transduction efficiency. To this
end, transductional targeting strategies have attempted to re-
engineer viral tropism such that target cell binding predicates
specificity. In parallel, strategies have been developed to
enhance the transcription selectivity of current vector systems
for tumor cells by limiting ectopic expression in non-tumor
cells, thus limiting treatment-associated toxicities. Transcrip-
tional targeting strategies employ the use of a tissue specific
promoter (TSP) to restrict transgene expression or viral repli-
cation to tumor cells. The ideal TSP for breast cancer would
exhibit the widest differential between 'tumor on/liver off'
expression profiles, which is key to ablation of liver toxicity from
ectopically localized adenovirus (Ad). It is noteworthy that
many promoters that exhibit specificity in plasmid based con-
structs do not show such specificity in Ad vectors. Thus, to
achieve the specificity of viral replication (virotherapy) or of
transgene expression (gene therapy) required in the context of
breast cancer gene therapy, it is necessary to evaluate pro-
moters and test them in the most stringent preclinical model
available. We have, therefore, recently explored tissue slice
technology via the Krumdieck Tissue Slicer [6], which offers a
powerful and representative ex vivo model system for preclin-
ical infectivity analysis of Ads. The human tumor tissue slice
model system represents the heterogeneity of the tumor and
maintains their three-dimensional structure in vitro [7].
Because cancer cell lines, passaged in vitro for years, may not
reflect the biology of tumors in vivo, we will herein compare the
specificity of TSPs of interest in cancer cell lines, primary
breast cancer cells, as well as breast cancer tissue slices
obtained using the Krumdieck Tissue Slicer.
In this study, we will examine epithelial glycoprotein (EGP)-2,
cyclooxygenase (Cox)-2, the α-chemokine SDF-1 receptor
(stromal-cell-derived-factor, CXCR4), secretory leukoprotease
inhibitor (SLPI) and survivin promoters. These promoters were
chosen because their corresponding genes are overex-
pressed in a variety of cancers, but are minimally expressed in
normal host tissues.
Heretofore, these different promoters have not been systemat-
ically explored in breast cancer. Our study will thus provide val-
uable information for breast cancer adenoviral based gene
therapy and virotherapy with respect to the most efficient tran-
scriptional targeting strategies.
Materials and methods
Breast cancer cell lines and cell line culture
Breast cancer cell lines MB-468, AU-565, GI-101, MB-231
and the normal human mammary epithelial cells MCF-12A
were obtained from the ATCC (American Type Culture Collec-
tion, Manassas, VA, USA). The 293 human transformed
embryonal kidney cell line was purchased from Microbix
(Toronto, Canada). All cell lines were maintained in a humidi-
fied 37°C atmosphere containing 5% CO2 and cultured with
the recommended media. Infections were performed in
medium with 2% v/v fetal bovine serum (Hyclone, Logan, UT,
USA).
Primary breast cancer cells and cell culture
Approval was obtained from the Institutional Review Board
(University of Alabama at Birmimgham, USA) for all studies on
human tissue. Primary fibroblasts were obtained from Dr NS
Banerjee (Department of Biochemistry and Molecular Genet-
ics, University of Alabama at Birmingham (UAB), Birnigham,
AL, USA). Human breast cancer samples from eight patients
who underwent surgery were obtained from the Department of
Pathology, UAB (Table 1), and normal breast tissue was
obtained from three patients who underwent mammoplasty.
Breast cancer tissue was obtained following removal of the
surgical specimen and confirmed to be breast cancer by a clin-
ical pathologist. Time from harvest to cell preparation was kept
at an absolute minimum (<2 h). Cells were obtained by
mechanical disruption. All primary breast cancer cells were
maintained in a humidified 37°C atmosphere containing 5%
CO2 and cultured in RPMI (Ruswell Park Memorial Institute,
supplemented with 10% v/v FCS, 2 mM glutamine, 100 U per
ml penicillin, and 100 µg per ml streptomycin).
Slice preparation with the Krumdieck Tissue Slicer
The Krumdieck tissue slicing system (Alabama Research and
Development, Birmingham, AL, USA) was used in accordance
with the manufacturer's instructions and previously published
techniques [6]. An 8 mm coring device (Alabama Research
and Development) was used to retrieve an 8 mm diameter
core of tissue from the human breast or liver tissue sample.
This was then placed in a slicer filled with ice-cold culture
media. Slice thickness was set at 250 microns using a tissue
slice thickness gauge (Alabama Research and Development)
and slices were cut using a reciprocating blade at 30 rpm.
Afterwards, these slices were stored in ice-cold culture
medium that served as a wash/equlibration solution between
preservation in University of Wisconsin (UW) solution
(ViaSpan, Barr Laboratories Inc., Pomona, NY, USA) and cul-
ture media [7].Available online http://breast-cancer-research.com/content/7/6/R1141
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Human primary breast cancer tissue slices and culture
Approval was obtained from the Institutional Review Board for
all studies on human tissue. Human breast cancer samples
were obtained from the same eight patients the primary breast
cancer cells were obtained from (Department of Pathology,
UAB; Table 1), and normal breast tissue was obtained from
three patients who underwent mammoplasty. All breast cancer
samples were flushed with UW solution before harvesting and
kept on ice in UW solution until slicing. Time from harvest to
slicing was kept at an absolute minimum (<2 h). Breast cancer
tissue slices were placed into 6-well plates (1 slice/well) con-
taining 2 ml of complete culture media (Ruswell Park Memorial
Institute, supplemented with 10% v/v FCS, 2 mM glutamine,
100 U per ml penicillin, and 100 µg per ml streptomycin [7]).
The plates were then incubated at 37°C/5% CO2 in a humidi-
fied environment. A plate rocker set at 60 rpm was used to agi-
tate the slices for 2 h and ensure adaequate oxygenation and
viability [8].
Human dermal fibroblasts were derived from adult skin by
trypsinization as described [9-11]. Human dermal fibroblasts
obtained from outgrowth of explant cultures were grown in
Dulbecco's modified Eagle's medium (Bio Whittaker, Rock-
land, Maine, USA) supplemented with 10% v/v FCS, 2 mM
glutamine, 100 U per ml penicillin, and 100 µg per ml
streptomycin and grown as monolayers on plastic Petri dishes
in the humidified atmosphere of a CO2 incubator at 37°C.
Fibroblasts were subcultured by trypsinization and used
between the third and fifth passage.
Human primary liver tissue slices and culture
Approval was obtained from the Institutional Review Board for
all studies on human tissue. Human liver samples were
obtained from three seronegative donor livers from the Depart-
ment of Surgery, UAB, prior to transplantation into recipients.
All liver samples were flushed with UW solution before har-
vesting and kept on ice in UW solution until slicing. Time from
harvest to slicing was kept at an absolute minimum (<2 h).
Liver tissue slices were placed into 6-well plates (1 slice/well)
containing 2 ml of complete culture media (Wiliam's Medium
E with 2 mM glutamine, 100 U per ml penicillin, and 100 µg
per ml streptomycin, 10% v/v FCS, 2 mM glutamine [7]). The
plates were then incubated at 37°C/5% CO2 in a humidified
environment. A plate rocker set at 60 rpm was used to agitate
the slices for 2 h and ensure adaequate oxygenation and via-
bility [8].
Viruses
AdCXCR4Luc, AdSurvivinLuc, AdSLPILuc, AdEGP-2Luc,
AdCox2MLuc and AdCMVLuc are replication-defective Ads
with a luciferase reporter gene in the E1 region under tran-
scriptional control of the different promoters and have been
described previously [12-15]. The viruses are all isogenic and
were propagated on 293 cells and purified by double CsCl
density centrifugation. Physical particle concentration (viral
particles/ml) was determined by OD260 reading, and functional
virus titers (plaque-forming units/ml) were determined by
plaque assay in 293 cells.
In vitro gene-transfer assays of breast cancer cells
Cell lines were plated on day 1 at 30,000 cells/well on 24-well
plates in 1 ml of 10% v/v GM (Growth Medium). On day 2,
cells were infected with recombinant Ads at a multiplicity of
infection (MOI) of 100 for 2 h in 200 µl of 2% v/v GM on a
rocker. Afterwards, cells were washed once with 1 ml of PBS,
and 1 ml of 10% v/v GM was added per well. Purified breast
cancer primary cells were plated at 10,000 cells/well on 96-
well plates in 100 µl GM on a rocker for 2 h. After 2 h, cells
Table 1
Stages and grades of breast cancer samples from eight patients
Patient Age Sex Race Stage Grade Size (cm) Histological type Laterality Adjuvant therapy Previous radiation ER PR Erb2
1 46 F AA pT1pN1pMx 3 1.8 Infiltrating mammary R No No - - +
2 42 F W pT2pN0pMx 3 2.2 Ductal L No No + + -
3 63 F W pT1cpN1pMx 3 2.0 Ductal, DCIS, LCIS L No No + + ++
4 53 F AA pT3pN1pMx ? 5.1 Ductal R (1998) No No + - -
R (2000) Adriamycin, Cytoxan, 
Taxol, Tamoxifen
Yes + + -
R (2004) Femara, Taxotere No - - -
Metastases to axilla L (2005) ? ? - + ++
5 47 F W pT2pN1pMx 2 2.5 Ductal R No No - - +
6 42 F AA pT2pN1pMx 2 2.1 Ductal R No No - - -
7 55 F W pT1pN0pMx 1 1.5 Ductal L No No + + -
8 64 F W pT1pN1pMx 3 1.9 Ductal R No No - - +
DCIS, ductal carcinoma in situ; F, female; L, left; LCIS, lobular carcinoma in situ; R, right; W, white; AA; African-american, ER, estrogen receptor, P, progesterone receptor.Breast Cancer Research    Vol 7 No 6    Stoff-Khalili et al.
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were infected with 100 viral particles/cell for 2 h in 20 µl of 2%
v/v GM on a rocker. Afterward, cells were washed once with
PBS, and 60 µl of 10% v/v GM were added per well. After 24
h, the GM was removed and cells were washed once with
PBS, lysed with 200 µl (cell lines) or 20 µl (primary cells) of
lysis buffer (Reporter Lysis Buffer, Promega, Madison, WI,
USA) and freeze-thawed three times. These samples (20 µl)
were mixed with 100 µl of luciferase assay reagent (Reporter
Lysis Buffer) and measured with a Berthold (Wildbad, Ger-
many) Lumat LB 9501. Standardization was accomplished by
setting values obtained with AdCMVLuc as 100% for each
cell line and primary cells of each patient.
Viral infection of human breast cancer and human liver 
tissue slices
For gene transfer assays of breast cancer and liver tissue
slices, all viral infections were performed with a MOI of 500 in
2% v/v FCS complete culture medium [7]. The cell number for
the tissue slices was estimated at 1 × 106 cells/slice based on
an approximate 10 cell slice thickness (approximately 250 µm)
and 8 mm slice diameter [7]. Infections were allowed to pro-
ceed for 24 h. The medium was removed and replaced with
10% v/v FCS complete culture medium. The infected breast
cancer tissue slices and human liver tissue slices were placed
in cell culture lysis buffer (Promega) and homogenized with an
ultra sonicator (Fisher Scientific Model 100, Pittsburgh, PA,
USA) at a setting of 15 watts for 10 s. The homogenate was
centrifuged to pellet the debris, and the luciferase activities
were measured using the Promega luciferase assay system.
Experiments were performed in triplicate. Protein concentra-
tion of the tissue homogenates was determined using a Bio-
Rad DC protein assay kit (Bio-Rad, Hercules, CA, USA) to
allow normalization of the gene expression data relative to the
number of cells.
Gene expression detected by real-time quantitative PCR
Total cellular RNA was extracted from 5 × 105 cells using the
RNeasy Mini kit (Qiagen, Valencia, CA, USA) followed by
treatment with RNase-free DNase to remove any possible con-
taminating DNA from the RNA samples. The fluorescent Taq-
Man probes and the primer pairs used for real-time PCR
analysis of the five gene mRNAs encoding Cox-2, CXCR4,
EGP-2, SLPI and survivin were designed using Primer Express
1.0 (Perkin-Elmer, Foster City, CA, USA) and synthesized by
Applied Biosystems (Foster City, CA, USA) (Table 2). Glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) was used as
an internal control. For the real-time PCR assay, each 9 µl
PCR reaction contained 3 mM MgCl2, 300 µM each of dATP,
dCTP, and dGTP, 600 µM dUTP, 100 nM of forward, reverse
primers, and probe, 1 U of rTth DNA polymerase, 0.025%
BSA, and RNase-free water. A plasmid standard or 1 µl of
RNA sample was added into each assay tube. Negative con-
trols with no template were performed for each reaction series.
The real-time PCR reaction was carried out using a LightCy-
cler™ System (Roche Molecular Biochemicals, Indianapolis,
IN, USA). Thermal cycling conditions were subjected to 2 min-
utes at 50°C, 30 minutes at 60°C, 5 minutes at 95°C, then 40
cycles of 20 s at 94°C, and 1 minute at 62°C. Data were ana-
lyzed with LightCycler software.
Histology
Sections (4 µm) of formalin-fixed, paraffin embedded tissue
slices of breast cancer tissue and normal tissue were stained
with hematoxylin-and-eosin following the standard procedure
and analyzed at 20× magnification with an Olympus BH2
microscope (Olympus, Tokyo, Japan). Photomicrographs were
captured using a SPOT camera (Diagnostic Instruments,
Sterling Heights, MI, USA) and assembled with Adobe Pho-
toshop 6.0 (Adobe Systems, San Jose, CA, USA).
Immunofluorescence
Presicion cut tissue slices obtained from breast cancer tissue
and normal breast tissue infected with AdCMVLuc and
AdCXCR4Luc were collected and frozen in isopentane chilled
in liquid nitrogen. Cryosections were cut at 10 µm, and the
slides were frozen at -80°C until used. The sections were air
dried after removing from the freezer, fixed in 4% v/v parafor-
maldehyde in PBS for 10 minutes and permeabilized in PBS
and 0.1% v/v Triton X-100 for 30 minutes at room tempera-
ture. Then tissue sections were incubated with 10% v/v nor-
mal rabbit serum in PBS for 30 minutes and goat anti-
luciferase primary antibody (G745A, Promega) at 1:50 dilution
Table 2
List of oligo pairs and probes used in quantitative RT-PCR
Gene Accession* Forward primer Reverse primer Probe
Cox-2 M90100 5'-TGATCCCCAGGGCTCAAAC-3' 5'-AGCTGGCCCTCGCTTATGA-3' 6FAMCTTTGCCCAGCACTTCACGCATCAGTAMRA
CXCR4 AF348491 5'-AACCAGCGGTTACCATGGAG-3' 5'-CTTCATGGAGTCATAGTCCC CTG-3' 6FAMACACTTCAGATAACTACACCGAGGAAATGGG
CTAMRA
EGP-2 NM_002354 5'-GGGCCCTCCAGAACAATGA-3' 5'-TGCACTGCTTGGCCTTAAAGA-3' 6FAMCCGCTCTCATCGCAGTCAGGATCATTAMRA
Survivin U75285 5'-TGGAAGGCTGGGAGCCA-3' 5'-GAAAGCGCAACCGGACG-3' 6FAMTGACGACCCCATAGAGGAACATAAAAAGCAT
TAMRA
SLPI NM_003064 5'-TCCTGACACTTGTGGCATCAA-3' 5'-GGCTTCCTCCTTGTTGGGTT-3' 6FAMTGCCTGGATCCTGTTGACACCCCTAMRA
Cox, cyclooxygenase; CXCR4, α-chemokine SDF-1 receptor; EGP, epithelial glycoprotein; SLPI, secretory leukoprotease inhibitor.
* Gene Bank Accession NumberAvailable online http://breast-cancer-research.com/content/7/6/R1141
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in PBS, 10% v/v normal rabbit serum, 1% v/v BSA, and 0.1%
v/v Triton X-100 overnight at 4°C. After washing three times
for 3 minutes each in PBS, the sections were incubated with
Alexa-488 (green fluorescence) conjugated donkey anti-goat
secondary antibody (A-11055, Molecular Probes, Eugene,
Oregon, USA) at 1:100 dilution in PBS for 1 h at room temper-
ature. After being washed in PBS, the sections were mounted
in 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) con-
taining fluorescence mounting medium (Vectashield, cata-
logue no. H-1200, Vector Laboratories Inc., Burlingame, CA,
USA). Green fluorescence for luciferase protein expression
was analyzed at ×20 objective magnification with an Olympus
Provis AX70 fluorescence microscope using FITC and DAPI
filters. Images were digitally recorded with an Axiocam charge-
coupled device digital camera (Carl Zeiss, Oberkochen, Ger-
many) and AxioVision 3.1 image capture software (Carl Zeiss).
Images were finally processed using Adobe Photoshop 6.0.
Statistics
Data are presented as mean values ± standard deviation. Sta-
tistical differences among groups were assessed with a two-
tailed Student's t-test. P < 0.05 was considered significant.
Results
Analysis of candidate promoters for transcriptional 
targeting of Ad-mediated gene expression in breast 
cancer cell lines
The transcriptional activities of the CXCR4, survivin, Cox-2,
SLPI and EGP-2 promoters driving luciferase expression in
recombinant Ad vectors was evaluated in four human breast
cancer cell lines (MB-468, AU-565, GI-101 and MB-231).
Cell lines were infected with the relevant adenoviral vectors at
a MOI of 10 (Fig. 1). AdCMVLuc was used to standardize for
varying transduction efficiencies between cell lines, and pro-
moter activities are therefore plotted as percentage of cytome-
galovirus (CMV) driven luciferase expression [12,13,16,17]. In
the breast cancer cell lines tested, each of the candidate
promoters demonstrated variable relative luciferase activity
between the different cell lines. The CXCR4 promoter, how-
ever, consistently showed a higher relative luciferase activity
compared to the other candidate promoters. These results
suggest that the CXCR4 promoter is promising for transcrip-
tional targeting in breast cancer cell lines.
Analysis of candidate promoters for transcriptional 
targeting of adenovirus-mediated gene expression in 
primary breast cancer cells
To more closely model the clinical situation, gene transfer
experiments were performed using unpassaged human pri-
mary breast cancer cells. Primary cancer cells were obtained
from breast cancer samples from eight patients; these patients
had different stages and grades of breast cancer (Table 1).
The primary breast cancer cells were infected with the relevant
Ad vectors at a MOI of 10 (Fig. 2a). Again, in most of the tumor
samples, the CXCR4 promoter displayed the highest luci-
ferase activity, consistent with the results obtained in breast
cancer cell lines. The exception to this trend was observed in
the sample derived from patient 2, which showed low overall
luciferase activity, with the highest activity in cells transduced
by the Ad containing the EGP-2 promoter rather than the
CXCR4 promoter. In most breast cancer samples, the relative
luciferase activity of each of the promoters was significantly
lower (p < 0.05) than the CMV promoter. However, in patient
4 (advanced, metastatic and recurrent breast cancer after
chemo- and radiotherapy), the CXCR4 promoter activity was
two-fold higher than the CMV promoter activity. These results
are in line with those obtained in breast cancer cell lines, with
the CXCR4 promoter showing the most promise for transcrip-
tional targeting in breast cancer.
Cox-2, EGP-2, SLPI, survivin and CXCR4 mRNA copy 
numbers correlate with the transcriptional activity of the 
corresponding promoters in primary breast cancer cells
To correlate transcriptional activity with the expression level of
the corresponding endogenous genes in the breast cancer
patient samples, Cox-2, EGP-2, SLPI, survivin and CXCR4
mRNA levels were assessed using quantitative reverse tran-
scriptase PCR (Fig. 2b). Whereas similar levels of expression
were seen for the housekeeping gene GAPDH among all the
patients (data not shown), the mRNA levels of examined genes
varied between the different patients. In this regard, differ-
ences in the mRNA levels of candidate genes strongly corre-
lated with the results of the promoter evaluation. With the
exception of patient 2, copy numbers for CXCR4 were signif-
icantly (p < 0.05) higher than those for EGP-2, SLPI, Cox-2
and survivin.
Figure 1
Evaluation of candidate promoters for transcriptional targeting of breast  cancer cell lines Evaluation of candidate promoters for transcriptional targeting of breast 
cancer cell lines. Luciferase activities in breast cancer cell lines (MB-
468, AU-565, GI-101 and MB-231). These cell lines were infected with 
AdCXCR4Luc, AdSurvivinLuc, AdCox2MLuc, AdSLPILuc, AdEGP-
2Luc and AdCMVLuc, respectively, at a multiplicity of infection of 100. 
Gene expression was measured 24 h after infection and is presented 
for the candidate promoters as percentage of cytomegalovirus pro-
moter activity in relative light units (RLU). Each bar presents the mean 
of three experiments (± standard deviation).
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To get an indication of the specificity of expression of these
genes of interest in breast cancer tissue, we next compared
the mean levels of gene expression between the eight breast
cancer patient samples to levels of gene expression in three
samples of individual normal primary unpassaged fibroblasts
(Fig. 3; note the different scales on the ordinate). Of the can-
didate genes tested, mRNA levels for CXCR4 (p < 0.001),
survivin (p < 0.05), SLPI (p < 0.05) and EGP-2 (p < 0.05)
were significantly lower in normal primary fibroblasts com-
pared with breast cancer tissue, while COX-2 showed no sig-
nificant difference. Thus, our studies indicate that of all the
tested candidate genes, the CXCR4  gene again demon-
strates the highest potential in transcriptional targeting in
breast cancer, with the highest mRNA copy number in breast
cancer samples and a significantly lower copy number in nor-
mal tissue represented by primary fibroblasts.
Analysis of candidate promoters for transcriptional 
targeting of adenovirus-mediated gene expression in 
primary breast tissue slices
Next, we investigated whether the results obtained with the
tested candidate promoters in primary breast cancer cells
could be reproduced in the most stringent available preclinical
model of precision cut breast cancer tissue slices. Primary
breast cancer tissue slices were obtained from the eight
breast cancer patient samples (Table 1). The CXCR4 pro-
moter consistently (with the exception of patient 2) achieved
the highest luciferase activity in the breast cancer tissue slices
(Fig. 4). These results are consistent with those from the
breast cancer cell lines and the primary breast cancer cell
model, with a strong correlation between the latter and the tis-
sue slices for each individual patient.
Figure 2
Analysis of candidate promoters for transcriptional targeting of adenovirus-mediated gene expression and correlation to the mRNA copy number of  the corresponding genes in primary breast cancer cells Analysis of candidate promoters for transcriptional targeting of adenovirus-mediated gene expression and correlation to the mRNA copy number of 
the corresponding genes in primary breast cancer cells. (a) Evaluation of candidate promoters for transcriptional targeting of primary breast cancer 
cells derived from patients. Primary breast cancer cells were isolated from eight patients and purified and infected with AdCXCR4Luc, AdSurvivin-
Luc, AdCox2MLuc, AdSLPILuc, AdEGP-2Luc or AdCMVLuc, at a multiplicity of infection of 100. Gene expression was measured 24 h after infec-
tion and is presented for the candidate promoters as percentage of cytomegalovirus promoter activity in relative light units (RLU). Each bar presents 
the mean of three experiments ± standard deviation. (b) Gene expression of candidate tumor-specific genes in breast cancer patient samples. Mes-
senger RNA was extracted from human primary breast cancer samples from eight patients and reverse-transcribed into cDNA. Real-time PCR was 
performed to evaluate the expression of the genes encoding cyclooxygenase (Cox)-2, epithelial glycoprotein (EGP)-2, secretory leukoprotease inhib-
itor (SLPI), survivin and the α-chemokine SDF-1 receptor (CXCR4). The mRNA copy numbers are normalized by the glyceraldehyde-3-phosphate 
dehydrogenase copy number. Each bar presents the mean of three experiments ± standard deviation.
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Analysis of candidate promoters for transcriptional 
targeting of adenovirus-mediated gene expression in 
normal breast tissue slices
To underline the specificity of the candidate promoters for
breast cancer samples, three patient samples consisting of
normal breast tissue were infected with the different transcrip-
tionally targeted adenoviral vectors. The results indicate that
the expression levels for all tested promoters were all below
0.6% relative to the CMV promoter in normal breast tissue
(Fig. 5). Finally, we visualized the selective transcriptional tar-
geting of the most promising vector tested in this study,
AdCXCR4, in breast cancer tissue versus normal breast tissue
(Fig. 6). In this regard, the expression pattern of the luciferase
protein, the product of the luciferase gene in the recombinant
Ad vector driven by the CXCR4 promoter and the CMV pro-
moter, was determined in breast cancer tissue slices and nor-
mal breast tissue slices using immunofluorescent detection.
Importantly, in normal breast tissue slices infected with
AdCXCR4, no luciferase protein expression could be
visualized, whereas in normal breast tissue infected with
AdCMV luciferase protein, expression was seen. These data
underline the previous results indicating that the CXCR4 pro-
moter is a promising selective tool for transcriptional targeting
of breast cancer.
Evaluation of the candidate promoters in human liver 
tissue slices
A key limitation for the use of a systemic adenoviral gene ther-
apy or virotherapy is the potential toxicity to non-target organs.
Although initial specificity of the promoters was demonstrated
by virtue of gene expression profiles in primary fibroblasts (Fig.
3), we next evaluated gene expression in the most relevant
context, the human liver. For this, each of the candidate pro-
moters was assessed for transgene expression in fresh-cut
human liver tissue slices. In this assay, transgene expression
induced by all the tested promoters (Cox-2, EGP-2, SLPI, sur-
vivin and CXCR4) was significantly less than that with the
CMV promoter (Fig. 7). Of note, the survivin promoter demon-
strated the lowest transgene expression of all the promoters
tested in human liver tissue slices. In addition, the CXCR4 pro-
moter displayed a significantly lower mean relative luciferase
activity in the human liver tissue slices (0.18%) than in the pri-
mary breast cancer samples (37.7%) or breast cancer tissue
slices (36.0%). These results demonstrate that all the tested
promoters, in the context of an Ad vector, possess the key
characteristic of a low level of expression in the human liver,
which is considered essential for use in cancer gene therapy
and virotherapy.
Discussion
The exploitation of novel therapeutic strategies merits a high
priority in the treatment of advanced, recurrent and metastatic
breast cancer. Adenoviral cancer gene therapy and
virotherapy have recently demonstrated promising clinical
results. It has become evident, however, that one of the pri-
mary factors preventing specific and efficient gene delivery
(gene therapy) or specific viral replication (virotherapy) in
breast cancer is the promiscuous tropism of Ad. For the treat-
ment of metastatic or advanced stages of breast cancer, intra-
venous delivery schemes of Ad vectors are desirable, but are
potentially associated with ectopic localization, principally to
the liver [18]. Thus, finding ways to target Ads to breast cancer
cells is mandatory to reduce the risk of nonspecific gene
expression and nonspecific adenoviral replication. TSPs are a
promising means to genetically limit transgene expression or
viral replication to tumor cells [19,20]. A wide range of promot-
ers has been evaluated for transcriptional targeting; however,
TSPs for use in breast cancer have not been systemically
explored. In the present study, therefore, we compare five can-
didate promoters (for Cox-2, EGP-2, SLPI, survivin and
CXCR4) for specific transcriptional control in breast cancer,
which might hold promise in the context of future gene therapy
or virotherapy regimes for this disease.
Figure 3
Comparison of gene expression profiles in breast cancer patient sam- ples and normal human fibroblasts Comparison of gene expression profiles in breast cancer patient sam-
ples and normal human fibroblasts. Messenger RNA was extracted 
from (a) human primary breast cancer samples from eight patients and 
(b) human primary fibroblasts from three patients and reverse-tran-
scribed into cDNA. Real-time PCR was performed to evaluate the 
expression of the genes encoding cyclooxygenase (Cox)-2, epithelial 
glycoprotein (EGP)-2, secretory leukoprotease inhibitor (SLPI), survivin 
and the α-chemokine SDF-1 receptor (CXCR4). The mRNA copy num-
bers are normalized by the glyceraldehyde-3-phosphate dehydroge-
nase copy number. Each bar presents the mean ± standard deviation. 
Asterisks indicate p < 0.05 for breast cancer versus normal fibroblasts.
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We chose the candidate promoters based upon established
links to the pathobiology of cancer. In this regard, Cox-2 is an
inducible isoform of the cylooxygenase family and is virtually
undetectable in most tissues under physiological conditions
[21]. Recently, however, overexpression of Cox-2 has been
reported in colon cancers associated with familial adenoma-
tous polyposis, as well as sporadic colorectal cancer, and in
cancers of the ovary, stomach, lung, esophagus, liver, pan-
creas and skin [15,22-26]. Approximately 50% of human
breast tumors have been reported to express Cox-2 [27,28].
SLPI is a 12 kDa serine protease inhibitor expressed in some
human carcinomas, including breast, ovary, lung and
endometrium [14,29]. Survivin is a member of the IAP (inhibi-
tor of apoptosis protein) protein family, members of which
have roles in the growth and progression of a variety of can-
cers. Recently, the gene encoding survivin has been
described as being selectively expressed in some of the most
common human neoplasms, such as breast cancer [30], pan-
creatic cancer [31], esophageal carcinoma [32], primary
glioblastoma [33], ovarian cancer [34], and melanomas [35],
but is undetectable in normally differentiated tissues [31].
Recently, EGP-2, also referred to as 17-1A or EpCAM, has
Figure 4
Evaluation of candidate promoters for transcriptional targeting of primary breast cancer tissue slices Evaluation of candidate promoters for transcriptional targeting of primary breast cancer tissue slices. Human breast cancer tissue slices were 
obtained from primary breast cancer samples using the Krumdieck Tissue Slicer. Slices were infected with AdCXCR4Luc, AdSurvivinLuc, 
AdSLPILuc, AdEGP-2Luc, AdCox2MLucor AdCMVLuc at a multiplicity of infection of 500. Gene expression was measured 24 h after infection and 
is presented for the candidate promoters as percentage of cytomegalovirus promoter activity in relative light units (RLU). All data points are of tripli-
cate slices; bars represent means ± standard deviation. Cox, cyclooxygenase; CXCR4, α-chemokine SDF-1 receptor; EGP, epithelial glycoprotein; 
SLPI, secretory leukoprotease inhibitor.
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been shown to be expressed as a stable transmembrane pro-
tein at high levels on a variety of epithelial tissue derived can-
cers, such as those of the breast, pancreas, gonads,
gastrointestinal, respiratory and urinary tracts [36]. The func-
tion of the transmembrane glycoprotein EGP-2 is still not well
understood, although recent reports have suggested it has a
role as a modulator of invasiveness and metastasis [37].
CXCR4, identified as a co-receptor for HIV-1, is a chemokine
receptor recently implicated in the metastatic homing of breast
cancer cells to alternative tissues [30]. It has been reported
that  CXCR4  gene expression is markedly up-regulated in
breast cancer cells, but is undetectable in normal mammary
primary epithelial and stromal cells [38]. Furthermore, recent
evidence points to the SDF-1α-CXCR4 complex as having a
role in progression to metastasis in several tumor contexts
[39,40].
As demonstrated in our study, the CXCR4 promoter showed
the highest level of expression and specificity for breast can-
cer tissue, corroborating the evidence in the literature for a
clear link to breast cancer pathobiology. Of note, although the
absolute level of expression was less compared to the CMV
promoter in the different patients (exception patient 4), it is
mainly the level of specificity for a particular tissue type that will
determine successful application in a clinical setting. Recent
studies evaluating promoter activity in the context of ovarian
cancer gene therapy have demonstrated that even promoter
activities lower than 5% can be regarded sufficient to achieve
therapeutic efficacy [41]. Unlike previous studies [7,27,28]
the gene encoding Cox-2 was not significantly over-expressed
in our breast cancer patient samples; however, variable gene
expression may result from different patient tumor samples.
Because human trials have suggested that established cell
lines may exhibit distinct properties different from original
breast cancer cells, likely due to the culturing in vitro, we
employed primary cultures to more closely resemble breast
cancer cell phenotypes in patients [42]. Primary cancer cells
Figure 5
Analysis of candidate promoters for transcriptional targeting of adenovi- rus-mediated gene expression in normal breast tissue slices Analysis of candidate promoters for transcriptional targeting of adenovi-
rus-mediated gene expression in normal breast tissue slices. Human 
normal breast tissue slices (from three patients undergoing mammo-
plasty) were infected with AdCXCR4Luc, AdSurvivinLuc, AdSLPILuc, 
AdEGP-2Luc, AdCox2MLuc or AdCMVLuc. Gene expression was 
measured 24 h after infection and is presented for the candidate pro-
moters as percentage of cytomegalovirus promoter activity in relative 
light units (RLU). All data points are of triplicate slices; bars represent 
means ± standard deviation.
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Figure 6
Visualization of luciferase expression pattern of AdCXCR4Luc and  AdCMVLuc in normal breast tissue slices versus breast cancer tissue  slices Visualization of luciferase expression pattern of AdCXCR4Luc and 
AdCMVLuc in normal breast tissue slices versus breast cancer tissue 
slices. The upper panels show the tissue morphology as revealed by 
hematoxylin-and-eosin staining of thin sections of (a) normal breast tis-
sue slices and (b) breast tissue slices. Representative indirect 
immunfluorescent detection of luciferase expression is shown in the 
lower panels for (a) human normal breast tissue slices and (b) breast 
cancer tissue slices infected with AdCXCR4Luc and AdCMVLuc. AdC-
MVLuc infected (a) normal breast tissue slices (lower left panel) and 
(b) breast cancer tissue slices (lower left panel) show immunofluores-
cent detection of the luciferase protein (green fluorescence), whereas 
(a) AdCXCR4 infected normal breast tissue slices (lower right panel) 
do not display luciferase activity. In contrast, (b) AdCXCR4 infected 
breast cancer tissue slices reveal luciferase activity (lower right panel). 
DAPI (4'6-diamidino-2-phenylindole 2HCL) staining (blue) indicates 
nuclei. Magnification ×200.
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were obtained by dissociation of epithelial tissue followed by
culturing of the cells. As mechanical and enzymatic cell disper-
sion will result in loss of polarity, changes in protein expression
patterns and loss of tissue structure, results obtained in these
primary cells might not reflect the in vivo situation with respect
to adenoviral infection [42]. This highlights the need to care-
fully evaluate the optimal Ad vector in the most stringent avail-
able preclinical model. For this reason, we have recently
introduced a novel ex vivo tissue slice model employing the
Krumdieck Tissue Slicer, which offers a powerful and repre-
sentative system for preclinical infectivity analysis of tumor
samples [7]. Similar findings in two different culture systems,
one being organotypic and the other being a primary
monolayer cell culture, validate our results. Futhermore, our
results demonstrate a strong correlation between the pro-
moter activity and expression levels of the corresponding
genes in primary breast cancer samples. This correlation indi-
cates that these results could be used to tailor transcriptionally
targeted vectors to individual patient tumors based on deter-
mination of the endogenous level of the promoter activity in
breast cancer samples.
For adenoviral gene therapy, ectopic transduction of non-
tumor target cells can elicit vector-associated toxicities, such
that hepatotropism is a major concern [43-45]. All of the pro-
moters in the present study have previously been shown to
have a 'liver off' status using mouse liver. We endeavored to
test the function of these promoters in the Krumdieck Tissue
Slice system, which closely reproduces the patient's situation
using human liver tissue slices. The human liver tissue slice
model has been shown previously to provide a valid means for
preclinical assay of potential Ad-based hepatotoxicity [7,46].
Importantly, the activity of all of the promoters used in this
study was low in human liver tissue slices.
Conclusion
This is the first time that precision cut tissue slice technology
has been applied in breast cancer. For this reason, we endea-
vored to test the five candidate promoters in precision cut tis-
sue slices of patient breast cancer samples. Clearly, the
activity of the CXCR4 promoter was superior in established
breast cancer cell lines, primary breast cancer cells, and pri-
mary breast cancer tissue slices, whereas the CXCR4 pro-
moter activity was low in normal breast tissue and, most
importantly, human liver. The CXCR4 gene plays a major role
in progression and metastasis of various tumor types and is,
therefore, a rational target for breast cancer therapy. This pro-
moter may thus be a promising candidate for tumor-specific
gene therapy and virotherapy applications in breast cancer.
The important value of this study is that we systemically
explored TSPs for breast cancer in the most stringent available
preclinical model. These data using comparative tumor and
non-tumor liver tissue slices may establish the foundation for
rational development of selective transcriptionally Ad-based
gene therapy and virotherapy.
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